

## REFERENCES

1. Are the number of cancer cases increasing or decreasing in the world? (2008). In World Health Organization [Online]. Available: <http://www.who.int/features/qa/15/en/index.html> [2011, April 10].
2. 10 facts about cancer (2008). In World Health Organization. [Online]. Available: [http://www.who.int/features/factfiles/cancer/01\\_en.html](http://www.who.int/features/factfiles/cancer/01_en.html) [2011, April 10].
3. Lunch of GLOBLCAN 2008. Section of Cancer Information 2010 (2010). International Agency for Research on Cancer [Online]. Available: [www.iarc.fr/en/media-centre/iarcnews/2010/GLOBOCAN2008.pdf](http://www.iarc.fr/en/media-centre/iarcnews/2010/GLOBOCAN2008.pdf) [2010, December 28].
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics 2009. *Ca Cancer J Clin* 2009; (59): 225-49.
5. Khuhaprema T. Current Cancer Situation in Thailand. *Thai J Toxicology* 2008; 23(2): 60-1.
6. Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P. Childhood leukemia. In *Cancer in Thailand Vol. IV, 1998-2000*. Bangkok: Ministry of Public Health, Ministry of Education; 2007
7. Li J, Thompson TD, Miller JW, Pollack L, Stewart SL. Cancer incidence

- among children and adolescents in the United States, 2001-2003. *Pediatrics* 2008; 121: 1470-77.
8. Online analysis: prediction the future burden of cancer (2010). Globocan 2008: cancer incidence and mortality worldwide in 2008 [Online]. Available: <http://globocan.iarc.fr/> [2010, October 20].
  9. Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P. Leukemia. In *Cancer in Thailand Vol. IV, 1998-2000*. Bangkok: Ministry of Public Health, Ministry of Education; 2007
  10. National Cancer Institute (2010). A snapshot of leukemia [Online]. Available: [www.cancer.gov/aboutnci/servingpeople/snapshots/leukemia.pdf](http://www.cancer.gov/aboutnci/servingpeople/snapshots/leukemia.pdf) [2011, April 10].
  11. Guide: Leukemia (2010). In American Cancer Society [Online]. Available: <http://www.cancer.org/> [2011, April 10].
  12. Leukemia (2011). In Wikipedia [Online]. Available: <http://en.wikipedia.org/wiki/Leukemia> [10 April 2011].
  13. Bennington J, Beckwith J. Tumors of the kidney, pelvis, and ureter. In *Atlas of Tumor Pathology, Armed Forces Institute of Pathology, Washington, DC., 1975*
  14. Menka AL, Van der Eb AJ, Jochemsen AG. The Wilms, tumor 1 Gene: Oncogene or Tumor Suppressor Gene. *Int Rev Cytol* 1998; 181: 151-212.
  15. Graidist P. The role of WT1 in breast and other cancers: oncogene or tumor suppressor gene? *Songkla Med J* 2009; 27: 435-49.

16. Yang L, Han Y, Saiz FS, Minden MD. A tumor suppressor and oncogenes: the WT1 story. *Leukemia*. 2007; 21: 868-76.
17. Kerst G, Bergold N, Viebahn S, Gieseke F, Kalinova M. WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase. *Leuk Res* 2008; 32 1393–99.
18. Bergmann L, Muarer U, Weidmann E. Wilms tumor gene expression in acute myeloid leukemia. *Leuk Lymphoma* 1997; 25: 435-43.
19. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, *et al.* WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. *Blood* 1994; 84: 3071-79.
20. Brieger J, Wiedmann E, Maurer U, Hoelzer D, Mitrou PS, Bergmann L. The Wilm's tumor gene is frequently expressed in acute myeloblastic leukemia and may provide a marker for residue blast cells detectable by PCR. *Ann Oncol*. 1995; 6: 811-6.
21. Holger Scholz and Karin M. Kirschner. A Role for the Wilms' Tumor Protein WT1 in Organ Development. *PHYSIOLOGY* 2005; 20: 54–9.
22. Akerele O. WHO's traditional medicine programme: progress and perspectives. *WHO Chron*. 1984; 38(2): 76-81.
23. Mantle D, Lennard TW, Pickering AT. Therapeutic applications of medicinal plants in the treatment of breast cancer: a review of their pharmacology, efficacy and tolerability. *Adverse Drug React Toxicol Rev* 2000; 19(3): 223-40.

24. Chin YW, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. *The AAPS Journal* 2006; 8(2): 239-53.
25. Manosroi J, Dhumtanoma P, Aranya ManosroiaA. Anti-proliferative activity of essential oil extracted from Thai medicinal plants on KB and P388 cell lines. *Cancer Letters* 2006; 235: 114–20.
26. Siripongvutikorna S, Thummaratwasik P, Huang Y. Antimicrobial and antioxidation effects of Thai seasoning, Tom-Yum. *LWT-Food Sci Technol.* 2005; 38: 347–52.
27. Hutadilok-Towatana N, Chaiyamutti P, Panthong K, Mahabusarakam W, Rukachaisirikul V. Antioxidative and free radical scavenging activities of some plants used in Thai folk medicine. *Pharm Biol.* 2006; 44: 221-8.
28. Lertsatitthanakorn P, Taweechaisupapong S, Aromdee C, Khunkittia W. In vitro bioactivities of essential oils used for acne control. *Int J Astrobiol* 2006; 16: 43-9.
29. Murakami A, Nakamura Y, Koshimizu K, Ohigashi H. Glyceroglycolipids from *Citrus hystrix*, a Traditional Herb in Thailand, Potently Inhibit the Tumor-Promoting Activity of 12-O-Tetradecanoylphorbol 13-Acetate in Mouse Skin. *J Agric Food Chem.* 1995; 43: 2779-83.
30. Garcia M et al. Global Cancer Facts and Figures 2007. ACS 2007.
31. Brayand F and Moller B. Predicting the future burden of cancer. *Nat Rev Cancer* 2006; (6): 63–74.
32. Molecular genetic medicine. Imprint San Diego: Academic Press, 1991.

33. Bos JL. *Ras* oncogenes in human cancer: A review. *Cancer Res* 1989; (49): 4682-9.
34. Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, et al. Cancer is a preventable disease that requires major lifestyle changes. *Pharma Res* 2008; (25): 2097-115.
35. Kinzler KW, Vogelstein B. Introduction. In *The genetic basis of human cancer*. 2<sup>nd</sup>ed. New York: McGraw-Hill, Medical Pub, 2002.
36. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000; 343:78–85.
37. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. *Carcinogenesis* 2000; 21: 379–85.
38. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. *Nat Rev Cancer* 2002; 2:331–41.
39. Mucci A, Wedren S, Tamimi RM, Trichopoulos D, Adami HO. The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. *J Intern Med* 2001; 249: 477–93.
40. Irigaray P, Newby JA, Clapp R, Hardell L, Howard V, Montagnier L, et al. Lifestyle-related factors and environmental agents causing cancer: an overview. *Biomed. Pharmacother* 2007; 61: 640–58.

41. The 1964 Report on Smoking and Health (2010). U.S. National Library of Medicine [Online]. Available: <http://profiles.nlm.nih.gov/NN/Views/Alpha> [10 April 2011].
42. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[ $\alpha$ ]pyrene adducts at lung cancer mutational hotspots in P53. *Science* 1996; 274: 430–2.
43. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-kappa B through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. *Carcinogenesis* 2002; 23: 1511–8.
44. Shishodia S, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaB alpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. *Cancer Res* 2004; 64: 5004–12.
45. Ichikawa H, Nakamura Y, Kashiwada Y, Aggarwal BB. Anticancer drugs designed by mother nature: ancient drugs but modern targets. *Curr Pharm Des* 2007; 13: 3400–16.
46. Tuyns AJ. Epidemiology of alcohol and cancer. *Cancer Res* 1979; 39: 2840–3.
47. Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of

the epidemiologic Cancer Prevention Requires Major Lifestyle Changes  
2113 evidence. *Oncogene* 2006; 25: 3756–70.

48. Szabo G, Mandrekar P, Oak S, Mayerle J. Effect of ethanol on inflammatory responses. Implications for pancreatitis. *Pancreatology* 2007; 7: 115–23.
49. Aggarwal BB. Nuclear factor-kappaB: the enemy within. *Cancer Cell* 2004; 6: 203–8.
50. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. *J Natl Cancer Inst* 1981; 66:1191–308.
51. Rodriguez C, McCullough M.L, Mondul AM, Jacobs EJ, Chao A, Patel *et al.* Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev* 2006; 15: 211.
52. Garcia-Closas R, Garcia-Closas M, Kogevinas M, Malats N, Silverman D, *et al.* Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. *Eur J Cancer* 2007; 43: 1731–40.
53. Tappel A. Heme of consumed red meat can act as a catalyst of oxidative damage and could initiate colon, breast and prostate cancers, heart disease and other diseases. *Med Hypotheses* 2007; 68: 562–4.
54. Toporcov TN, Antunes JL, Tavares MR. Fat food habitual intake and risk of oral cancer. *Oral Oncol* 2004; 40: 925–31.

55. Sasaki YF, Kawaguchi S, Kamaya A, Ohshita M, Kabasawa K, Iwama K, *et al.* The comet assay with 8 mouse organs: results with 39 currently used food additives. *Mutat Res* 2002; 519: 103–19.
56. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. *Cancer Epidemiol Biomarkers Prev* 1997; 6: 387–400.
57. Blumberg BS, Larouze B, London WT, Werner B, Hesser J, Millman I, *et al.* The relation of infection with the hepatitis B agent to primary hepatic carcinoma. *Am J Pathol* 1975; 81: 669–82.
58. Hagen TM, Huang S, Curnutte J, Fowler P., Martinez V, Wehr CM, *et al.* Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. *Proc Natl Acad Sci USA* 1994; 91: 12808–12.
59. Maria ND, Colantoni A, Fagioli S, Liu GJ, Rogers BK, Farinati F, *et al.* Association between reactive oxygen species and disease activity in chronic hepatitis C. *Free Radic. Biol Med* 1996; 21: 291–5.
60. Koike K, Tsutsumi T, Fujie H, Shintani Y, Kyoji M. Molecular mechanism of viral hepatocarcinogenesis. *Oncology* 2002; 62(1): 29–37.
61. Belpomme D, Irigaray P, Hardell L, Clapp R, Montagnier L, Epstein S, *et al.* The multitude and diversity of environmental carcinogens. *Environ Res* 2007; 105: 414–29.



62. Guan YS, He Q, Wang MQ, Li P. Nuclear factor kappa B and hepatitis viruses. *Expert Opin Ther Targets* 2008; 12: 265–80.
63. McKenzie SB. Textbook of hematology .2<sup>nd</sup> ed. Maryland: Williams & Wilkins; 1996.
64. McKenzie SB. Textbook of hematology .2<sup>nd</sup> ed. Maryland: Williams & Wilkins; 1996. 733 pp
65. Bain BJ. Leukaemia diagnosis. Chichester, NJ: Wiley-Blackwell; 2010.
66. Ross JA, Robinson LL. MLL rearrangements in infant leukemia: is there a higher frequency in female? *Leu Res* 1997; 21: 793-5.
67. Jackson N, Menson BS, Zarina W, Zawawi N, Naing NN. Why is acute leukemia more common in males? A possible sex-determined risk linked to the ABO blood group genes. *Ann Hematol* 1999; 78: 233-6.
68. Dorak MT, Betnett AK, Worwood M. Hemochromatosis gene in leukemia and lymphoma. *Leuk Lymphoma* 2002; 43: 467-77.
69. Posthuma EF, Falkenburg JH, Apperly JF, Gratwohl A, Hertenstein B, Schipper RF, *et al.* HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant registry, *Leukemia* 2000, 14: 859-62.
70. Horwitz M, Goode EL, Jarvik GP. Anticipation in familial leukemia. *Am J Hum* 1996; 59: 990-8.

71. Kwong YL, Ng MH, Ma SK, Familial acute myeloid leukemia with monosomy 7: late onset and involvement of a multipotential progenitor cell. *Cancer Genet cytogenet* 2000; 110: 124-7.
72. Halse H, Clemmensen IH, Mikkelsen M. Risks of leukemia and solid tumors in individual with Down's syndrome. *Lancet* 2000; 355: 165-9.
73. Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, *et al.* Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type1. *Blood* 1998; 92: 267-72.
74. Felix CA, Megonigal MD, Chervinsky DS, Leonard DG, Tsuchida N, Kakati S, *et al.* Association of germline of p53 mutation with MLL segmental jumping translocation in treatment-related leukemia. *Blood* 1998; 91: 4451-6.
75. Voskaridou E, Terpos E, Komninaka V, Eftyhiadis E, Mantzourani M, Loukopoulos D. Chronic myeloid leukemia with marked thrombocytosis in a patient with thalassemia major: complete hematological remission under the combination of hydroxyurea and anagrelide. *Br J Haematol* 2002; 116(1): 155-7
76. Sotomayer EA, Glasser L, Acute lymphoblastic leukemia in sickle cell disease. *Arch Pathol Lab Med* 1999; 123: 745-6.
77. Biggs BG, Vaughan W, Colombo JL, Sanger W, Purtilo DT. Cystic fibrosis complicated by acute leukemia. *Cancer* 1986; 57: 2441-3.

78. Abbas Z, Malik I, Khan A. Sequential induction of aplastic anemia and acute leukemia by chloramphenicol. *J Pak Med Assoc* 1993; 43: 58-9.
79. Kusher BH, Heller G, Cheung NK, Wollner N, Kramer K, Bajorin D, *et al.* High risk of leukemia after short-term dose-intensive chemotherapy for rheumatoid arthritis. *J Clin Oncol* 1998; 16: 3016-20.
80. Hambach L, Eder M, Dammann E, Batter K, Stucki A, Heil G, *et al.* Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for lymphoma: an assessment of risk factor. *Blood* 2000; 95: 1588-93.
81. Strick R, Strissel PL, Borgers S, Smoth SL, Rowly JD. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. *PNAS USA* 2000; 97: 4790-5.
82. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The *PML-RAR $\alpha$*  fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. *Cell* 1991; 66: 675-84.
83. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveid G. Structural organization of the bcr gene and its role in the Ph' translocation. *Nature* 1985; 315: 758-61.
84. Licht JD, Sternberg DW. The molecular pathology of acute myeloid leukemia. *Hematology* 2005; 137-42.

85. Blair A, Dosemeci M, Heineman EF. Cancer and other causes of death among male and female farmers from twenty-three states. *Am J Ind Med* 1993; 23(5): 729–42.
86. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, *et al.* Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. *Blood* 2003; 102(8) 2951-7.
87. Matutes E, Pickl WF, Veer MV, Morilla R, Swansbury J, Strobl H. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. *Blood*, 2011; 117(11): 3163-71.
88. Lichtman MA, Beutler E, Kipps TJ, Kaushansky K, Prchal JT. Acute myeloid leukemia. In Willims hematology. 7<sup>th</sup>ed. McGraw-Hill Medical; USA; 2008.
89. Raimondi SC, Ravindranath Y, Chang MN, *et al.* Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study - POG 8821. *Blood* 1999; 94: 3707-16.
90. Hiddemann W, Kern W, Schoch C, *et al.* Management of acute myeloid leukemia in elderly patients. *J Clin Oncol.* 1999; 17: 3569-76.
91. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia

- (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. *Blood* 2001; 98: 1302-11.
92. Mro´zek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics of acute myeloid leukemia. *Semin Oncol* 1997; 24: 17-31.
93. Mro´zek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. *Int J Hematol* 2000; 72: 261-71.
94. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML10 trial. *Blood* 1998; 92: 2322-33.
95. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. *Blood* 2001; 98: 1312-20.
96. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. *Blood* 2010; 116: 2224-8.
97. Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. *J Clin Oncol* 2008; 26(29): 4791-7.

98. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland C, Serve H, Büchner T, Haferlach T, Hiddemann W. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease". *Blood* 2002; 100 (1): 59–66.
99. Slovak M, Kopecky K, Cassileth P, Harrington D, Theil K, Mohamed A, Paietta E, Willman C, Head D, Rowe J, Forman S, Appelbaum F. "Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study". *Blood* 2000; 96(13): 4075–83.
100. Bain BJ. FAB classification. *Leukaemia diagnosis*. 2nd ed, Oxford: Blackwell Science, 1999.
101. Catovsky D. *Cytochemistry in the classification of leukemias*. 2<sup>nd</sup> ed, The Leukemic cell. Edinburgh : Churchill Livingstone, 1991.
102. Roumier C, Eclanche V, Imbert M, Davi F, MacIntyre E, Gerand R, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a reported of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH). *Blood* 2003; 101: 1277-83.
103. Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, Barnard DR. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is

- associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. *Blood* 2007; 109(6): 2314-21.
104. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H, *et al.* Definition of a standard-risk group in children with AML. *Brit J Haematol* 1999; 104(3): 630-9.
105. Rodak BF, Fritsma GA, Doig K. Acute leukemia. In Hematology clinical principles and applications. 3<sup>rd</sup>ed. Elsevier Inc: Philadelphia: USA, 2002.
106. Catovsky D. Immunophenotyping in the classification of leukemias. 2<sup>nd</sup> ed, The Leukemic cell. Edinburgh : Churchill Livingstone, 1991.
107. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. *Am J Med* 1977; 63: 125-30.
108. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. *Science* 1960; 132: 1497.
109. Federl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. *New Engl J Med* 1999; 341(3): 164-72.
110. Drew Provan and John Gribben. Molecular hematology. Oxford : Blackwell Science, 2000
111. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* 2002; 100: 2292-302.

112. Byrd JC, Stilgenbauer S, Film IW. Chronic lymphocytic leukemia. *Hematology* 2004; 163-83.
113. Zwiebel JA, Cheson BD, Chronic lymphocytic leukemia: staging and prognostic factor. *Semin Oncol* 1998; 25: 42.
114. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. *Rec Clin Exp Hematol* 2000; 4: 5-21.
115. Harris NL. Mature B-cell neoplasms. In: Jaffe ES, Haris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumors. pathology and genetics. Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001: 127-30, 138-41.
116. Bennett JM, Catovsky D, Daneil MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukemias. *J Clin Pathol* 1989; 42: 567-84.
117. Haris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 case of an uncommon aggressive neoplasm. *Blood* 1997; 89: 4501-13.
118. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM and Moore PS. *Science* 1994; 266: 1865-9.
119. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. *Blood* 1975; 46: 219-34.



120. Binet JL, Leparrier M, Dighiero G, Charron D, Vaugier G, Beral HM, *et al.* A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. *Cancer* 1997; 40(2): 855–64.
121. Lee SB and Haber DA. Wilms tumor and the *WT1* gene. *Exp Cell Res* 2001; 264: 74–99.
122. Hastie ND. The genetics of Wilms' tumor—a case of disrupted development. *Annu Rev Genet* 1994; 28: 523–558.
123. Riccardi, V. M., Sujansky, E., Smith, A. C., and Francke, U. Chromosomal imbalance in the aniridia-Wilmstumor association: 11p interstitial deletion. *Pediatrics* 1978; 61: 604-10.
124. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, *et al.* Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell* 1990; 60: 509–20.
125. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene *WT1*. *Proc Natl Acad Sci USA* 1991; 88: 9618–22.
126. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (*WT1*) gene mutations in acute leukaemia. *Hematol Oncol* 2010; 28(1): 13-9.
127. Rauscher FJ. The *WT1* Wilms' tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. *FASEB J* 1993; 7: 896–903.

128. Bruening W, Moffett P, Chia S, Heinrich G, and Pelletier J. Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product. *FEBS Lett* 1996; 393: 41–7.
129. Discenza MT, Pelletier J. Insights into the physiological role of WT1 from studies of genetically modified mice. *Physiol Genomics* 2004; 16: 287–300.
130. Wang ZY, Qiu QQ, Enger KT, Deuel TF. *Proc Natl Acad Sci USA* 1993; 90: 8896–900.
131. Sharma PM, Bowman M, Madden SL, Rauscher FJ III, and Sukumar S. RNA editing in the Wilms' tumor susceptibility gene, WT1. *Genes Dev* 1994; 8: 720–31.
132. Rauscher FJ, III. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. *FASEB J* 1993; 7: 896–903.
133. Ryan G, Steele-Perkins V, Morris JF, Rauscher FJ, Dressler GR. Repression of Pax-2 by WT1 during normal kidney development. *Development* 1995; 121: 867-75.
134. Lee SB, Huang K, Palmer Ra, Truong VB, Herzlinger D, Kolquist KA. The wilms tumor suppressor *wilms* encodes a transcriptional activator of *amphiregulin*. *Cell* 1999; 98: 663–73.
135. Maheswaran S, Park S, Bernard A, Morris JF, Rauscher II FJ, Hilly DE. Physical and functional interaction between WT1 and p53 proteins. *Proc Natl Acad Sci USA* 1993; 90: 5100-4.

136. Murata Y, Kudo, Sugiyama H, Toyoshima K, Akiyama T. The Wilms tumor suppressor gene WT1 induced G1 arrest and apoptosis in myeloblastic leukemic M1 cells. *FEBS Letters* 1997; 409: 41-5.
137. Morris JF, Madden SL, Tournay OE, Cook DM, Sukhatme VP, and Rauscher FJ III. Characterization of the zinc finger protein encoded by the WT1 Wilms' tumor locus. *Oncogene* 1991; 6: 2339-4.
138. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, and Housman DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. *Proc Natl Acad Sci USA* 1991; 88: 9618-22.
139. Dallosso AR, Hancock AL, Brown KW, Williams AC, Jackson S, Malik K. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours. *Hum Mol Genet* 2004; 13: 405-15.
140. Bruening W and Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. *J Biol Chem* 1996; 271: 8646-54.
141. Scharnhorst V, Dekker P, van der Eb AJ, and Jochemsen AG. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties. *J Biol Chem* 1999; 274: 23456-62.
142. Armstrong JF, Pritchard JK, Bickmore WA, Hastie ND, Bard JB. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. *Mech Dev* 1993; 40: 85-97.

143. Moore AW, Schedl A, McInnes L, Doyle M, Hecksher SJ, Hastie ND. YAC transgenic analysis reveals Wilms' Tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. *Mech Dev* 1998; 79: 169-84.
144. Moore AW, McInnes L, Kreidberg J, Hastie ND, Schedl A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. *Development* 1999; 126: 1845-57.
145. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. WT-1 is required for early kidney development. *Cell* 1993; 74: 679-91.
146. Herzer U, Crocoll A, Barton D, Howells N, Englert C. The Wilms tumor suppressor gene wt1 is required for development of the spleen. *Curr Biol* 1999; (9): 837-40.
147. Wagner KD, Wagner N, Vidal VP, Schley G, Wilhelm D, Schedl A, Englert C, Scholz H: The Wilms' tumor gene Wt1 is required for normal development of the retina. *EMBO J* 2002; 21: 1398-405.
148. Wagner KD, Wagner N, Schedl A. The complex life of WT1. *J Cell Sci* 2003; 116: 1653-8.
149. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T. Immunohistochemical detection of WT1 protein in a variety of cancer cells. *Modern Pathology* 2006; 19: 804-14.

150. Silberstein GB, Van Horn K, Strickland P, Robert CT Jr, Daniel CW. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. *Proc Natl Acad Sci USA* 1997; 94: 8132–7.
151. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, *et al.* The expression of Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. *Jpn J Cncer Res* 1999; 90(2): 194-204.
152. Oji Y, Miyoshi S, Maeda H, Hayashi S, Amaki H, Nakatsuka S. Overexpression of the Wilms' Tumor gene Wt1 in de novo lung cancers. *Int J Cancer* 2002; 100: 297–303.
153. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H *et al.* Very low frequencies of human normal CD34+ haematopoietic haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. *Br J Haematol* 2002; 116: 409–20.
154. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. *Exp Hematol* 1997; 25: 312–20.
155. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. *Blood* 1996; 88: 2267-78.
156. Alberta JA, Springett GM, Rayburn H, Natoli TA, Loring J, Kreidberg JA, *et al.* Role of the WT1 tumor suppressor in murine hematopoiesis. *Blood* 2003; 101: 2570–74.

157. Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, *et al.* AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. *Blood* 2006; 107: 3303–12.
158. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (*WT1*) in human leukemias. *Leukemia* 1992; 6: 405–940.
159. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilms' tumor gene, *WT1*, in human leukemia cells. *Leukemia* 1993; 7: 970–7.
160. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, *et al.* WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. *Blood* 1994; 84: 3071-9.
161. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, *et al.* Growth inhibition of human leukemic cells by *WT1* (Wilms Tumor Gene) antisense oligodeoxynucleotides: implications for the involvement of *wt1* in leukemogenesis. *Blood* 1996; 87(7): 2878-84.
162. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, *et al.* Aberrant overexpression of the Wilms Tumor Gene (WT1) in human leukemia. *Blood* 1997; 89(4): 1405-12.
163. Svedberg H, Chylicki K, Gullberg U. Downregulation of Wilms' tumor gene (WT1) is not a prerequisite for erythroid or megakaryocytic differentiation of the leukemic cell line K562. *Exp Hematol* 1999; 27: 1057-62.

164. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. *J Exp Med* 1979; 149: 969-74.
165. Kaffir lime (2011). In Wikipedia [Online]. Available: [http://en.wikipedia.org/wiki/Kaffir\\_lime](http://en.wikipedia.org/wiki/Kaffir_lime) [2011, March 27].
166. Manner, H.I., R.S. Buker, V. Easton Smith, and C.R. (2006). Citrus species (citrus), ver. 2.1. In: Elevitch, C.R. (ed.). Species Profiles for Pacific Island Agroforestry [Online]. Available: <http://www.traditionaltree.org> [2011, March 27].
167. Kaffir Lime (2006). In the Epicentre [Online]. Available <http://www.theepicentre.com/Spices/kaffir.html> [2011, March 27].
168. Kaffir lime (2011). In Wikipedia [Online]. Available: <http://th.wikipedia.org/wiki/มะกรูด> [2011, March 27].
169. Kasuan N, Yunus M, Rahiman MHF, Aris RSR, Taib MN. Essential oil composition of Kaffir lime: Comparative analysis between controlled steam distillation and hydrodistillation extraction process. Proceedings of 2009 IEEE Student Conference. *SCORED*. UPM Serdang, Malaysia. Sept. 2009, p. 479-82.
170. Chaisawadi S, Thongbutr D, Kulamai S. Clean production process of freeze dried kaffir lime powder for medicinal herb and cosmetic use. *ISHS Acta Hort* 2008; 786: 193-200.

171. Hongratanaworakit T, Tapaneeyasin P, Nuamlert J, Chansiri A, Hongrattanavorakit N. Development of skin whitening preparations from kaffir lime oil (*Citrus hystrix*). *Planta Med* 2006; 72.
172. Foo-trakul P, Watchiradatsatien C. Development of anti-dandruff shampoo from kaffir lime which is the byproduct of food industry. *Kasetsart J. (Nat. Sci.)* 2005; 39: 725-9.
173. Lawrence BM, Hogg JW, Terhune ST and Podimuang V. Constituents of the leaf and peel oils of *Citrus hystrix*, D.C. *Phytochemistry* 1971; 10: 1404-5.
174. Chanthaphon S, Chanthachum S, Hongpattarakere T. Antimicrobial activities of essential oils and crude extracts from tropical *Citrus* spp. against food-related microorganisms. *Songklanakarin J Sci Technol* 2008; 30(1): 125-31.
175. Waikedrea J, Dugay A, Barrachinac I, Herrenknecht C, Cabalion P, Fournet A. Chemical composition and antimicrobial activity of the essential oils from new caledonian citrus macroptera and citrus hystrix. *Chem Biodivers* 2010; 7: 871-7.
176. Yunas M. Comparison of % composition of essential oils from peels and leaves of kaffir lime (*Citrus hystrix*) by hydrodistillation and solvent (ethyl acetate) extraction. 2009
177. Lota ML, Serra D, Tomi, Casanova J. Chemical variability of peel and leaf essential oils of mandarins from *Citrus reticulata* Blanco. *J Biochem Syst Ecol* 2000; 28: 61-78.



178. Tachakittirungrod S, Okonogi S, Chowwanapoonpoh S. Study on antioxidant activity of certain plants in Thailand. Mechanism of antioxidant action of guava leaf extract. *Food Chemistry* 2007; 103: 381-8.
179. Tangkanakul P, Auttaviboonkul P, Niyomwit B, Lowvitoon N, Charoenthawat P, Trakoontivakorn G. Antioxidant capacity, total phenolic content and nutritional composition of Asian foods after thermal processing. *International Food Research Journal* 2009; 16: 571-80.
180. Harborne JB and Williams CA. Notes on flavonoid survey. In B.Mathew (Ed.): *A review of Allium section Allium Kew*. Royal Botanic Garden, UK, pp. 41-44, 1996.
181. Mackeen MM, Ali AM, El-Sharkawy SH, Mnap MY, Salleh KM, Lajis NH, Kawazu K. Antimicrobial and cytotoxic properties of some Malaysian traditional vegetable Ulam. *Int J Pharm* 1997; 35: 174-8.
182. Jantarach J, Thanaboripat D. The Efficacy of Ethyl Acetate Extract of *Trichoderma* Culture Broth on Growth Inhibition and Aflatoxin Production by *Aspergillus flavus* IMI 242684. *KMITL Sci Tech J* 2010; 10(1): 19-29.
183. Nanasombat S, Lohasupthawee P. Antibacterial activity of crude ethanolic extracts and essential oils of spices against salmonellae and other enterobacteria. *KMITL Sci Tech J* 2005; 5(3): 527-38.
184. Hirasa K, Takemasa M. *Spice Science and Technology*. New York, Marcel Dekker Inc., 1998.

185. Kim J, Marshall MR, Wei C. Antibacterial activity of some essential oil components against five foodborne pathogens. *J Agr Food Chem* 1995; 43(11): 2839-45.
186. Juven BJ, Kanner J, Schved F, Weisslowicz H. Factors that Interact with the Antibacterial Action of Thyme Essential Oil and its Active Constituents. *J Appl Bacteriol* 1994; 76: 626-31.
187. Tawatsin A, Wratten SD, Scott RR, Thavara U, Techadamrongsin Y. Repellency of volatile oils from plants against three mosquito vectors. *J Vector Ecol* 2001; 26: 76-82.
188. Poulouse S M, Harris ED, Patil BS. Antiproliferative effects of citrus against human neuroblastoma and colonic adenocarcinoma cells. *Nutr Cancer* 2006; 56(1): 103-12.
189. Patil JR, Jayaprakasha GK, Murthy KNC, Tichy SE, Chetti MB, Patil BS. Apoptosis-mediated proliferation inhibition of human colon cancer cells by volatile principles of *Citrus aurantifolia*. *Food Chem* 2009; 114: 1351-8.
190. Wattenberg LW, Coccia JB. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone carcinogenesis in mice by D-limonene and citrus fruit oils. *Carcinogenesis* 1991; 12(1): 115-7.
191. Sugiyama S, Umehara K, Kuroyanagi M, Ueno A, Taki T. Studies on the differentiation inducers of myeloid leukemic cells from Citrus species. *Chem Pharm Bull* (Tokyo) 1993; 41(4): 714-9.

192. Mak NK, Wong-Leung YL, Chan SC, Wen J, Leung KN, Fung MC. Isolation of anti-leukemia compounds from *Citrus reticulata*. *Life Sci* 1996; 58(15): 1269-76.
193. Ampasavate C, Okonogi S, Anuchapreeda S. Cytotoxicity of extracts from fruit plants against leukemic cell lines. *Afr J Pharm Pharmacol* 2010; 4(1): 013-21.
194. Livek KJ, Schmittgent TD. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* 2001; 25: 402-8.
195. Hinoi T, Kishida S, Koyama S, Ikeda M, Matsuura Y, Kikuchi A. Post-translational modifications of Ras and Ral are important for the action of Ral GDP dissociation stimulator. *J Biol Chem* 1996; 271(33): 19710-6.
196. Anuchapreeda S, Tima S, Duangrat C, et al. Effect of pure curcumin, demethoxycurcumin and bisdemethoxycurcumin on *WT1* gene expression in leukemic cell lines. *Cancer Chemothe Pharmacol* 2008; 62(4): 585-94.
197. Boyd MR. In *Anticancer drug development guide: preclinical screening, clinical trials, and approval*; Teicher, B. A., Ed. Humana: Totowa, NJ, 1997.